Synlogic (SYBX) Stock Price, News & Analysis

Company Overview

Synlogic Inc. is a clinical-stage biotechnology company pioneering the development of synthetic biotic medicines—engineered live bacterial therapies designed to treat a range of rare and severe diseases. By leveraging advances in synthetic biology and metabolic engineering, Synlogic creates genetically modified probiotic strains that perform therapeutic functions within the human body, such as metabolizing toxic compounds or modulating immune responses. The company’s platform focuses on optimizing safety, manufacturability and targeted delivery of synthetic biotics through proprietary strain design and rigorous preclinical evaluation.

The company’s lead programs include SYNB1618, an investigational therapy for phenylketonuria (PKU) that breaks down excess phenylalanine in the gastrointestinal tract, and SYNB1020, a candidate aimed at reducing ammonia levels in patients with urea cycle disorders. Synlogic is also advancing early-stage programs in nonalcoholic steatohepatitis (NASH) and immuno-oncology, where engineered strains are being evaluated for their ability to modulate host metabolic and immune pathways. Each program is supported by translational biomarker strategies and collaborative efforts with academic and industry partners.

Founded in 2013 as a spin-out from the Massachusetts Institute of Technology, Synlogic is headquartered in Cambridge, Massachusetts, with research, development and manufacturing facilities designed to support both preclinical and clinical operations. The company has conducted clinical trials across North America and Europe, and maintains collaborations with leading pharmaceutical companies to accelerate clinical development and broaden the potential applications of its synthetic biotic platform.

Synlogic is led by a management team and board of directors with deep expertise in synthetic biology, drug development and commercialization. The executive leadership brings together veterans from the biotechnology sector, along with the company’s founding scientists, to drive innovation in live microbial therapies. With a robust pipeline and strategic partnerships, Synlogic aims to establish synthetic biotics as a new therapeutic modality for patients with high unmet medical needs.

Key Stats

• Today's Range: $1.20 to $1.25
• 50-Day Range: $1.08 to $1.28
• 52-Week Range: $0.90 to $1.88
• Volume: 2,054 shs
• Average Volume: 16,772 shs
• Market Capitalization: $14.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Synlogic Stock Analysis - MarketRank™

Synlogic scored higher than 23% of companies evaluated by MarketBeat, and ranked 911th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Synlogic.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Synlogic are expected to grow in the coming year, from ($2.71) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Synlogic is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synlogic is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synlogic has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.53% of the float of Synlogic has been sold short.

Short Interest Ratio / Days to Cover

Synlogic has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synlogic has recently increased by 0.26%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synlogic does not currently pay a dividend.

Dividend Growth

Synlogic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.53% of the float of Synlogic has been sold short.

Short Interest Ratio / Days to Cover

Synlogic has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synlogic has recently increased by 0.26%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Synlogic has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Synlogic this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synlogic insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.02% of the stock of Synlogic is held by insiders.

Percentage Held by Institutions

63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYBX Stock Analysis - Frequently Asked Questions

How have SYBX shares performed this year?

Synlogic's stock was trading at $1.40 at the beginning of 2025. Since then, SYBX stock has decreased by 12.5% and is now trading at $1.2250.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) released its earnings results on Thursday, March, 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04.

When did Synlogic's stock split?

Shares of Synlogic reverse split on the morning of Thursday, September 28th 2023.The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Sangamo Therapeutics (SGMO), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYBX
• CIK: 1527599
• Web: www.synlogictx.com
• Phone: (617) 401-9975
• Fax: 512-681-5201
• Employees: 80
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: -291,924.97%
• Return on Equity: 10.91%
• Return on Assets: 7.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,433.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 11,700,000
• Free Float: 11,343,000
• Market Cap: $14.33 million
• Optionable: Optionable
• Beta: 0.55